Investigating immunologic mechanisms in vivo is a fundamental part of translational medical research. TRON provides an integrated pipeline for all stages of in vivo studies, from planning the experiments to analyzing the results. We use the latest data analysis tools to provide valuable experimental data for developing future clinical applications.
All common in vivo application techniques are carried out at TRON in cooperation with the central facilities of the Medical Center of the Johannes Gutenberg University Mainz. Our in-house imaging facility features in vivo luminescence and fluorescence technologies. We also focus strongly on advancing technique across the board and are consistently expanding our spectrum of technologies and services. One example is our establishment of intralymphatic RNA application, which is now in routine use.
Two particularly important areas of investigation at TRON are the in vivo efficacy of T and B cell vaccines, and the set-up and characterization of tumor models. We explore nanoparticle and liposome formulations for tumor therapeutics and the in vivo uptake mechanism for coding RNA.
We also employ next-generation transgenic models tailored to meet the needs of translational medicine. To generate improved physiological models, our research team employs knock-in and knock-out, BAC (bacterial artificial chromosome), recombinase-mediated and tet on/off technologies. Investigation of transgenic models at TRON combines state-of-the-art information technology, molecular biology and mouse biotechniques. The unit’s infrastructure and equipment includes classical cloning and recombineering, PCR and Southern blot screening, ES cell culture facilities and a modern microinjection setup.
In addition to stem cell research and developmental biology, the tools above are used to more effectively translate human disease into preclinical models. Such an approach allows for the qualified testing of novel therapeutic strategies in an in vivo setting that closely mirrors the human condition and is thus essential to turning biomedical discoveries into patient benefits.